International Journal of Clinical Biochemistry and Research

Print ISSN: 2394-6369

Online ISSN: 2394-6377

CODEN : IJCBK6

International Journal of Clinical Biochemistry and Research (IJCBR) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award more...

Article type

Review Article


Article page

270-272


Authors Details

Kowsalya R*


Article Metrics


View Article As

 


Downlaod Files

   






Article statistics

Viewed: 553

PDF Downloaded: 258


MicroRNAs as biomarkers in prostate cancer: A mini review


Review Article

Author Details : Kowsalya R*

Volume : 10, Issue : 4, Year : 2023

Article Page : 270-272

https://doi.org/10.18231/j.ijcbr.2023.049



Suggest article by email

Get Permission

Abstract

Among men one of the most common cancers identified globally is prostate cancer. Although the serum prostate specific antigen remains important for prognosis and diagnosis, the PSA assay is not highly accurate. In the search for improved minimally invasive methods as a biomarker, the expression patterns of circulating miRNAs have a potential importance and are emerging as a promising candidate as prognostic markers for prostate cancer.
 

Keywords: Prostate cancer, miRNAs, Biomarkers.


How to cite : Kowsalya R, MicroRNAs as biomarkers in prostate cancer: A mini review. Int J Clin Biochem Res 2023;10(4):270-272

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.